5 GLP-1 weight loss myths in India that need to go away

Myth 1: 'It's only for people with diabetes'

Semaglutide and tirzepatide were both first approved for diabetes, but dedicated weight-management versions (like Wegovy for semaglutide) are approved for chronic weight management in people without diabetes too, based on BMI and other health criteria.

Myth 2: 'You'll gain all the weight back the moment you stop'

Weight regain after stopping abruptly is a real and well-documented pattern, which is exactly why a proper plan includes a maintenance and gradual de-escalation phase rather than a hard stop. Regain isn't inevitable — it's a planning problem, and a good doctor-led plan addresses it directly.

Myth 3: 'It's only for the wealthy'

This was truer before March 2026. Since semaglutide's patent expired in India and 40+ generic brands entered the market, monthly costs for generic semaglutide have dropped to a fraction of branded pricing — making it accessible to a much wider range of people than a year ago.

"The cost conversation in India changed meaningfully in 2026 — it's worth re-checking numbers you might have seen even a year ago."

Myth 4: 'It's basically a shortcut, real weight loss should come from diet and exercise'

These medicines work by changing appetite and fullness signals — the same biological systems that diet and exercise also act on, just less powerfully for many people. Doctors overwhelmingly recommend pairing the medicine with diet and activity changes, not replacing them, because that combination is what drives the best long-term outcomes and protects muscle mass.

Myth 5: 'All GLP-1 medicines are basically the same, so it doesn't matter which one I pick'

Semaglutide and tirzepatide work differently (one hormone pathway versus two), have different average efficacy in trials, different side-effect profiles, and different costs. Which one is a better starting point genuinely depends on your specific profile — that's exactly what our fit check is built to help you think through, before your doctor confirms the final decision.

If you've been holding off because of something you read a while back, it might be worth a fresh look — both the medical evidence and the India pricing landscape have moved quickly in the last year.